He headed the Laboratoires Chauvin for 17 years (until its acquisition by Bausch and Lomb), prior to joining Neurotech, a French biotechnology company where he served as chief executive officer until 2004. Since then, he has taken an active role as a director in the development of a number of pharmaceutical and biotechnology companies.